Clinical Observation Of Rh-Endostatin Combined With Chemotherapy For Metastatic Breast Cancer

Purpose:To assess the effect and security of rh-endostatin combined with chemotherapy for metastatic breast cancer.Methods:The cases of metastatic breast cancer from Jan.2008to Dec.2011that met the inclusion criteria which were confirmed by pathology or cytology. The measurable metastatic tumors were proved by the computer tomography or magnetic resonance image. The patients were treated by chemotherapy combined with rh-endostatin. Chemotherapy regimens were worked out respectively according to the prevous regimens that may be effective for the patients. Rh-endostatin7mg/m2was administered intravenously from day1to day14. The interval was twenty-one days for each cycle of chemotherapy. Short term effect was evaluated after two cycles, side effect were assessed every cycle. Curative effect evaluation standard is Response Evaluation Criteria in Solid Tumors1.1(RECIST1.1), and adverse reaction evaluation standard is the National Cancer Institute-Common Toxicity Criteria3.0(NCI-CTC3.0).Results:14patients were female,with the median age37. All patients underwent the treatment for40cycles, each one1-7cycles, average cycle2.8. Among the11patients which were assessable, there is no patients reach complete response (CR),6patients reach partial remission(PR),3patients reach stable disease(SD), and2patients disease progress(PD). The overall response rate (RR) is54.5%. The disease control rate (DCR) is81.8%. The time to progress (TTP) is3to35months,and the median time to progress (mTTP) is6months.Eight of the14patients survived, and6patients died.The overall survival time(OS)is3-69months, and the median overall survival time(mOS) is13.25months. There were7cases using the regimen which contained taxanes. Among these,6patients reach PR, the other one reach PD.The RR is85.7%, the TTP is1to35months, the mTTP is7.5months,the OS is3to69months, the mOS is13.5months.Toxicity can be assessed of all the14patients. The main side effects are leucopenia, hemoglobin descended, thrombocytopenia, alopecia, fatigue and vomiting. In the hematology toxicity, leucopenia took up a rate of85%,which Ⅲ-Ⅳ degrees rate of35%.The main non-hematology toxicity are ⅠⅡ degree, there are Ⅲ degrees nausea and vomiting, constipation and lung infection each in1, vaginal bleeding in1. All kinds of adverse reations can be restored after symptomatic treatments. In this clinical observation, we did not find the dmage of the function of heart, liver or kidney. Conclusion:Preliminary observation of Rh-endostatin combined with chemotherapy in the treastment of metastatic breast cancer assured curative effects. Toxicity could be tolerated and high safety.